← Back to front page
Asia · Regional markets · Moneycontrol

Buy GlaxoSmithKline Pharmaceuticals; target of Rs 2900: ICICI Securities

Published by Moneycontrol · India 9 h ago
Buy GlaxoSmithKline Pharmaceuticals; target of Rs 2900: ICICI Securities
Moneycontrol

Detailed summary

ICICI Securities is bullish on GlaxoSmithKline Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2900 in its research report dated November 06, 2026.

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Opening of the article, excerpted from Moneycontrol. To read the rest, open the article on the publisher's site.

Read the full article on Moneycontrol Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.moneycontrol.com)

Also worth reading

CNBC-TV18

SEBI's new settlement rules kick in: Fees, 90-day deadline and application process explained

 Business Standard

Coca-Cola's India bottling arm HCCH files DRHP for 997.5 million-share IPO

 Tech in Asia

Meet the 15 top-funded startups and tech companies in Vietnam

 The Straits Times Business

Ex-ST Engineering, Singtel exec Low Ka Hoe to succeed Tong Yew Heng as Netlink NBN Trust CEO

 The Financial Express

Diwali rally lights up portfolios of ace investors

 Business Recorder

CCP approves Nestlé–Platinum equity joint venture